Welcome to our dedicated page for Mural Oncology PLC news (Ticker: MURA), a resource for investors and traders seeking the latest updates and insights on Mural Oncology PLC stock.
This page provides a historical news archive for Mural Oncology plc (formerly Nasdaq: MURA), a biotechnology company described in its public communications as a clinical-stage immuno-oncology company. The company focused on using a protein engineering platform to develop cytokine-based immunotherapies for the treatment of cancer and maintained its registered office in Dublin, Ireland, with primary facilities in Waltham, Massachusetts.
The news flow around Mural Oncology includes several key themes documented in its press releases. One major strand is the clinical development and subsequent discontinuation of its lead product candidate, nemvaleukin alfa. Announcements in March and April 2025 reported that the Phase 3 ARTISTRY-7 trial in platinum-resistant ovarian cancer did not meet its primary endpoint and that, after reviewing additional data from the Phase 2 ARTISTRY-6 trial in melanoma, the company decided to discontinue all clinical development of nemvaleukin and terminate other research and development activities, including IL-18 and IL-12 programs.
Another central theme in Mural Oncology’s news record is its exploration of strategic alternatives and eventual acquisition. On April 15, 2025, the company announced that it would explore strategic alternatives focused on maximizing shareholder value, and later updates described cost-conservation measures, including a workforce reduction of approximately 90%. On August 20, 2025, Mural Oncology and XOMA Royalty Corporation announced a definitive transaction agreement under which XRA 5 Corp., a wholly owned subsidiary of XOMA Royalty, would acquire the entire issued and to be issued share capital of Mural via an Irish High Court sanctioned scheme of arrangement.
Subsequent news items document shareholder approvals at meetings held on October 24, 2025, the sanction of the scheme by the High Court of Ireland, and the effective date of the acquisition on December 5, 2025. The company also announced that admission of Mural shares to trading on the Nasdaq Global Market was cancelled with effect from the evening of December 4, 2025. Together, these releases provide a detailed timeline of Mural Oncology’s transition from an independent Nasdaq-listed biotech to a wholly owned subsidiary of XOMA Royalty Corporation.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.